Maravai LifeSciences (MRVI) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 125.5% versus a loss of 35.3%. Over five years, NAMS leads with a +117.2% price change compared with -79.9% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.76 billion vs $2.52 billion), about 1.1 times the size.
Maravai LifeSciences converts more of its revenue into profit, with a net margin of -70.4% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | NAMS |
|---|---|---|
| Share price | $7.44 | $21.58 |
| Market cap | $2.76B | $2.52B |
| 1-day change | +3.19% | +1.48% |
| YTD return | +128.92% | -39.40% |
| 1-year return | +125.45% | -35.30% |
| 5-year return | -79.94% | +117.16% |
| EPS (TTM) | $-0.53 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $185.74M | $22.50M |
| Revenue growth (YoY) | -28.34% | -50.61% |
| Net income (latest FY) | $-130.77M | $-203.82M |
| Gross margin | 18.30% | — |
| Operating margin | -115.89% | -1002.90% |
| Net margin | -70.41% | -905.74% |
| 52-week high | $9.42 | $42.21 |
| 52-week low | $2.55 | $20.91 |
| Distance from 52-week high | -21.02% | -48.88% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +5.24% | +130.13% |
| Average volume | 3.36M | 1.36M |
| Shares outstanding | 148.99M | 116.90M |
| Employees | 415 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed NAMS by 160.8 percentage points over the past year.
- Maravai LifeSciences is more profitable, keeping -70.4 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- Maravai LifeSciences grew revenue faster in its latest fiscal year (-28.34% vs -50.61%).
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
MRVI vs NAMS FAQ
Which is bigger, Maravai LifeSciences or NewAmsterdam Pharma N.V.?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.76B compared with $2.52B for NewAmsterdam Pharma N.V. (NAMS).
Which stock has performed better over the past year, MRVI or NAMS?
MRVI returned +125.45% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are Maravai LifeSciences and NewAmsterdam Pharma N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.